site staff are prepared, that inspections are handled professionally, and that responses and CAPA to inspection findings are managed within mandated timelines.

Scope

This SOP applies to all personnel at sponsor, CRO, and clinical sites who may be involved in regulatory inspections. It includes inspection preparation, conduct, document management, inspector interactions, closing meetings, official responses, CAPA development, and post-inspection learning.

Responsibilities

• QA Manager: Leads inspection preparation, manages inspection conduct, and coordinates responses.
• Sponsor/CRO Management: Provides resources, approves response letters, and oversees CAPA implementation.
• PI/Site Staff: Ensures ISF completeness, subject safety records, and availability for interviews.
• Clinical Operations: Provides TMF documents, monitoring reports, and ensures staff readiness.
• Regulatory Affairs: Maintains correspondence history, submissions, and approvals.
• Pharmacovigilance: Provides SAE/SUSAR documentation and compliance evidence.
• IT/Systems: Manages inspector access to eSystems and ensures secure, read-only configurations.

Accountability

Head of QA is accountable for ensuring regulatory inspections are managed according to this SOP. The PI is accountable for site-level preparedness and responses. Senior sponsor management is accountable for approving responses and ensuring systemic CAPA.

Procedure

1. Inspection Preparation
1.1 Conduct mock inspections at sponsor, CRO, and sites.
1.2 Maintain an Inspection Readiness Binder containing organizational chart, contact list, study list, TMF/ISF indices, and SOP inventory.
1.3 Ensure training logs, CVs, delegation logs, and essential documents are up-to-date.
1.4 Prepare SMEs for interviews and ensure backroom/frontroom setup is complete.

2. Inspector Arrival and Opening Meeting
2.1 Verify inspector credentials and record details in Inspector Attendance Log (Annexure-1).
2.2 Conduct opening meeting: introduce staff, present inspection agenda, clarify scope.
2.3 Provide inspector information pack (org chart, facility map, key contacts, safety info).

3. Document Handling
3.1 Maintain a Document Request Log (Annexure-2) for every request, including time, document, owner, and status.
3.2 Retrieve documents only from controlled systems (TMF/ISF, validated eSystems).
3.3 Provide controlled copies to inspectors, mark “INSPECTOR COPY” where permitted.
3.4 Ensure originals remain secured unless legally required.

4. Conducting Interviews
4.1 Pre-brief SMEs to provide concise, truthful, document-referenced answers.
4.2 Assign Notetaker to record all questions and answers (Annexure-3 Interview Log).
4.3 Escalate complex queries to backroom for validation before answering.

5. Daily Management
5.1 Conduct internal daily huddles to review pending requests, issues, and risks.
5.2 Track issues in Inspection Issues Log (Annexure-4).
5.3 Implement immediate corrections where permissible and document actions.

6. Closing Meeting
6.1 Attend closing meeting with inspectors.
6.2 Record all observations, clarifications, and potential classifications.
6.3 Do not argue; seek clarifications and acknowledge receipt of findings.

7. Post-Inspection Responses
7.1 Upon receipt of inspection letter (FDA Form 483, EMA letter, CDSCO memo), log it in Inspection Response Tracker (Annexure-5).
7.2 Perform root cause analysis for each observation.
7.3 Draft response letters in compliance with regulatory timelines (15 business days for FDA).
7.4 Obtain sponsor QA and management approval before submission.
7.5 File final responses in TMF and ISF.

8. CAPA Integration
8.1 Translate each observation into CAPA using CAPA Form (Annexure-6).
8.2 Assign responsibility and due dates.
8.3 Track CAPA implementation and closure.
8.4 Conduct effectiveness checks via follow-up audits.

9. Archiving
9.1 Archive inspector credentials, attendance log, document request log, issues log, inspection responses, and CAPA evidence.
9.2 Retain documents for at least 15 years or per jurisdiction.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• QA: Quality Assurance
• TMF/ISF: Trial Master File / Investigator Site File
• CAPA: Corrective and Preventive Action
• SME: Subject Matter Expert

Documents

1. Inspector Attendance Log (Annexure-1)
2. Document Request Log (Annexure-2)
3. Interview Log (Annexure-3)
4. Inspection Issues Log (Annexure-4)
5. Inspection Response Tracker (Annexure-5)
6. CAPA Form (Annexure-6)

References

• ICH E6(R2/R3) – Good Clinical Practice
• US FDA – Bioresearch Monitoring (BIMO) Inspections
• EMA – GCP Inspection Procedures
• CDSCO – Clinical Trial Inspections
• WHO – GCP Inspection Readiness

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, QA Auditor
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Quality

Annexures

Annexure-1: Inspector Attendance Log

Date	Inspector Name	Agency	Credentials Verified	Signature
12/09/2025	John Smith	US FDA	Yes	Signed
13/09/2025	Maria Gonzalez	EMA	Yes	Signed

Annexure-2: Document Request Log

Date/Time	Requested Document	Owner	Provided (Y/N)	Remarks
12/09/2025 10:15	Informed Consent File – Site 002	Coordinator	Y	Provided
12/09/2025 11:05	IP Accountability Log	Pharmacist	Y	Verified

Annexure-3: Interview Log

Date	Interviewee	Role	Questions	Responses Summary
12/09/2025	Dr. Neha Verma	PI	Consent process, SAE reporting	Answered with references

Annexure-4: Inspection Issues Log

Date	Observation	Category	Immediate Action	Status
13/09/2025	Missing delegation signature	Minor	Obtained and filed	Closed
13/09/2025	Late SAE submission	Major	Escalated to PV	Open

Annexure-5: Inspection Response Tracker

Date Received	Observation	Response Due	Owner	Status
15/09/2025	IP temperature excursion logs missing	30/09/2025	QA	Drafting

Annexure-6: CAPA Form

Observation	Root Cause	Corrective Action	Preventive Action	Owner	Status
Consent version mismatch	Uncontrolled document use	Reconsent affected subjects	Checklist updated + retraining	Site PI	Open

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Quality

For more SOPs visit: Pharma SOP